Elo, Petri
Tadayon, Sina
Liljenbäck, Heidi
Teuho, Jarmo
Käkelä, Meeri
Koskensalo, Kalle
Saunavaara, Virva
Virta, Jenni
Veres, Tibor Z.
Kiviniemi, Aida
Saraste, Antti
Marjamäki, Päivi
Airas, Laura
Jalkanen, Sirpa
Roivainen, Anne http://orcid.org/0000-0002-4006-7977
Funding for this research was provided by:
Turku University Hospital (13856)
Academy of Finland (258814)
Turku University Foundation (NA)
the Finnish MS Foundation (NA)
Jane ja Aatos Erkon Säätiö
Article History
Received: 4 August 2017
Accepted: 9 April 2018
First Online: 1 May 2018
Authors’ information
: Sirpa Jalkanen is the founder of VAP-1.
: All study protocols and procedures were reviewed and approved by the national Animal Experiment Board of Finland and the Regional State Administrative Agency for Southern Finland (license number ESAVI/3046/04.10.07/2014) and conducted in accordance with the relevant European Union directive.
: Sirpa Jalkanen is a shareholder in Faron Ventures Ltd. Other authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.